Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report

Immune checkpoint inhibitors (ICIs) represent a recently introduced class of agents active in head and neck squamous cell carcinoma (HNSCC). For a subgroup of patients with recurrent or metastatic disease, long-term benefit can be achieved: maintaining a sustained response to immunotherapy is theref...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonomo, Pierluigi, Lucidi, Sara, Desideri, Isacco, Scotti, Vieri, Casati, Marta, Palomba, Annarita, Ciabatti, Cinzia, Garlatti, Pietro, Massi, Daniela, Gallo, Oreste, Livi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186263/
https://www.ncbi.nlm.nih.gov/pubmed/32368625
http://dx.doi.org/10.1016/j.ctro.2020.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186263/
https://www.ncbi.nlm.nih.gov/pubmed/32368625
http://dx.doi.org/10.1016/j.ctro.2020.04.007

Ejemplares similares